CJC-1295 With DAC 2 mg

Manufacturer: Hilma Biocare, Europe

Pharmaceutical name: Drug Affinity Complex: Growth Hormone-Releasing Factor

Pack: 1 vial (2 mg)

CJC-1295 peptide with DAC, also referred to as DAC:GRF, is a synthetic version that mimics a segment of the naturally occurring growth hormone releasing hormone (GHRH). The chemistry of CJC-1295 with DAC is centered around the initial 29 amino acids of endogenously produced GHRH, as these amino acids are required for full biological activity.

 

However, this peptide has undergone additional modifications by replacing four amino acids, which enhances its stability and potency compared to the original CJC-1295 without DAC. These alterations enable the peptide to permanently bind to the protein albumin in the body, thereby decreasing its degradation and oxidation, thus improving stability. Additionally, the modified amino acids boost the peptide's binding affinity to the GHRH receptor, increasing its potency. GHRH is essential for the natural release of growth hormone and is critical for optimal growth during development.

 

CJC-1295 functions by promoting growth hormone secretion through its interaction with GHRH receptors and should trigger the release of the full spectrum of growth hormone peptides typically secreted by the pituitary gland. These hormones promote increases in bone density, collagen production, and enhance immune function, as well as stimulating the production of lean muscle mass.

 

CJC-1295 with DAC can be used alongside growth hormone releasing peptides for improved results in peptide cycling. It is frequently combined with growth hormone replacement peptides (GHRP) such as GHRP-6 or GHRP-2. Using CJC-1295 DAC with GHRPs accelerates fat loss and weight management and promotes anabolic effects through growth hormone-induced fat breakdown. Overall, CJC-1295 with DAC enhances protein synthesis and supports the development of lean muscle tissue. This peptide also aids in quicker recovery from injuries, reduces body fat, and increases muscle mass. The growth-promoting effects of CJC-1295 DAC will also enhance cell growth and division, benefiting skin health, healing, and immune function.

 

This peptide must not be mistaken for CJC-1295 without DAC, as their chemical characteristics are significantly distinct, influencing dosing. CJC-1295 DAC has a half-life of approximately 8 days post-injection. Injections of CJC-1295 with DAC should be administered subcutaneously, and can be done weekly at doses of 100 mcg or 200 mcg due to its prolonged half-life. This peptide cycling approach will produce a sustained increase in growth hormone. A weekly injection of CJC-1295 with DAC can be combined (stacked) with other GHRPs, such as GHRP-6 or GHRP-2.

 

Numerous researchers have documented the growth-enhancing effects and safety of GHRH when administered to children with growth hormone deficiencies. Various treatment methods, including intravenous pulses, intranasal delivery, subcutaneous injections, and continuous infusion, have been evaluated, demonstrating that the growth-promoting effectiveness of GHRH correlates with the dosage and frequency of administration. No unexpected adverse effects have been reported following extended treatment, regardless of the delivery method. However, some mild side effects may occur, such as fatigue, euphoria (head rush), water retention, and sensations of tingling or numbness. Adhering to the suggested dosage will help minimize the risk of side effects.